{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:35:30Z","timestamp":1787020530346,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Commonwealth Transfusion Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Typically minor ABO incompatible platelet products are transfused without any incident, yet serious hemolytic transfusion reactions occur. To mitigate these events, ABO \u2018low titer\u2019 products are used for minor ABO incompatible transfusions. We sought to understand the role of IgM\/IgG and complement activation by anti-A on extravascular hemolysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Samples evaluated included (i) Group O plasma from a blood donor whose apheresis platelet product resulted in an extravascular transfusion reaction, (ii) Group O plasma from 12 healthy donors with matching titers that activated complement (N\u2009=\u20096) or not (N\u2009=\u20096), and (iii) Group O sera from 10 patients with anti-A hemolysin activity. A flow cytometric monocyte erythrophagocytosis assay was developed using monocytes isolated by immunomagnetic CD14-positive selection from ACD whole blood of healthy donors. Monocytes were frozen at \u2212\u200980\u00a0\u00b0C in 10% dimethyl sulfoxide\/FBS and then thawed\/reconstituted on the day of use. Monocytes were co-incubated with anti-A-sensitized fluorescently-labeled Group A1\u2009+\u2009RBCs with and without fresh Group A serum as a source of complement C3, and erythrophagocytosis was analyzed by flow cytometry. The dependency of IgM\/IgG anti-A and complement C3 activation for RBC erythrophagocytosis was studied. Anti-A IgG subclass specificities were examined for specific samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The plasma and sera had variable direct agglutinating (IgM) and indirect (IgG) titers. None of 12 selected samples showed monocyte-dependent erythrophagocytosis with or without complement activation. The donor sample causing a hemolytic transfusion reaction and 2 of the 10 patient sera with hemolysin activity showed significant erythrophagocytosis (&gt;\u200910%) only when complement C3 was activated. The single donor plasma and two sera demonstrating significant erythrophagocytosis had high IgM (\u2265\u2009128) and IgG titers (&gt;\u20091024). The donor plasma anti-A was IgG1, while the patient sera were an IgG3 and an IgG1 plus IgG2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High anti-A IgM\/IgG titers act synergistically to cause significant monocyte erythrophagocytosis by activating complement C3, thus engaging both Fc\u03b3- and CR1-receptors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-020-02378-w","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T09:04:05Z","timestamp":1590656645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Complement activating ABO anti-A IgM\/IgG act synergistically to cause erythrophagocytosis: implications among minor ABO incompatible transfusions"],"prefix":"10.1186","volume":"18","author":[{"given":"Priyanka","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem Q.","family":"Anani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome L.","family":"Gottschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8727-1679","authenticated-orcid":false,"given":"Gregory A.","family":"Denomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"2378_CR1","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1365-2141.1990.tb04356.x","volume":"75","author":"R Carr","year":"1990","unstructured":"Carr R, Hutton JL, Jenkins JA, Lucas GF, Amphlett NW. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol. 1990;75:408\u201313.","journal-title":"Br J Haematol"},{"key":"2378_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/MOH.0b013e328358b135","volume":"19","author":"NM Dunbar","year":"2012","unstructured":"Dunbar NM, Ornstein DL, Dumont LJ. ABO incompatible platelets: risks versus benefit. Curr Opin Hematol. 2012;19:475\u20139.","journal-title":"Curr Opin Hematol"},{"key":"2378_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1046\/j.0041-1132.2004.00604.x","volume":"44","author":"DS Fauzie","year":"2004","unstructured":"Fauzie DS, Shirey R, Thoman S, Bensen-Kennedy D, King KE. The risk of hemolytic transfusion reactions due to passively acquired ABO antibodies: a retrospective study of Non-Group O Adult Recipients of Group O Plateletpheresis. Transfusion. 2004;44:36.","journal-title":"Transfusion"},{"key":"2378_CR4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.5858\/2007-131-909-TOPCAP","volume":"131","author":"MK Fung","year":"2007","unstructured":"Fung MK, Downes KA, Shulman IA. Transfusion of platelets containing ABO-incompatible plasma: a survey of 3156 North American laboratories. Arch Pathol Lab Med. 2007;131:909\u201316.","journal-title":"Arch Pathol Lab Med"},{"key":"2378_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1600-0609.1993.tb00150.x","volume":"50","author":"JM Heal","year":"1993","unstructured":"Heal JM, Rowe JM, McMican A, Masel D, Finke C, Blumberg N. The role of ABO matching in platelet transfusion. Eur J Haematol. 1993;50:110\u20137.","journal-title":"Eur J Haematol"},{"key":"2378_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1537-2995.2004.03290.x","volume":"44","author":"CD Josephson","year":"2004","unstructured":"Josephson CD, Mullis NC, Van Demark C, Hillyer CD. Significant numbers of apheresis-derived group O platelet units have \u201chigh-titer\u201d anti-A\/A, B: implications for transfusion policy. Transfusion. 2004;44:805\u20138.","journal-title":"Transfusion"},{"key":"2378_CR7","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/j.1537-2995.2012.03574.x","volume":"52","author":"MS Karafin","year":"2012","unstructured":"Karafin MS, Blagg L, Tobian AA, King KE, Ness PM, Savage WJ. ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions. Transfusion. 2012;52:2087\u201393.","journal-title":"Transfusion"},{"key":"2378_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1046\/j.1537-2995.1989.29589284135.x","volume":"29","author":"EJ Lee","year":"1989","unstructured":"Lee EJ, Schiffer CA. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion. 1989;29:384\u20139.","journal-title":"Transfusion"},{"key":"2378_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1046\/j.1537-2995.1998.38198141498.x","volume":"38","author":"B Mair","year":"1998","unstructured":"Mair B, Benson K. Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets. Transfusion. 1998;38:51\u20135.","journal-title":"Transfusion"},{"issue":"Suppl 2","key":"2378_CR10","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1111\/trf.13147","volume":"55","author":"WA Flegel","year":"2015","unstructured":"Flegel WA. Pathogenesis and mechanisms of antibody-mediated hemolysis. Transfusion. 2015;55(Suppl 2):S47\u201358.","journal-title":"Transfusion"},{"key":"2378_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/B978-0-12-397164-7.00062-8","volume-title":"Transfusion medicine and hemostasis (Second Edition)","author":"CD Josephson","year":"2013","unstructured":"Josephson CD. Delayed hemolytic transfusion reactions. Transfusion medicine and hemostasis (Second Edition). Amsterdam: Elsevier; 2013. p. 409\u201312."},{"key":"2378_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000154811","volume":"35","author":"E Strobel","year":"2008","unstructured":"Strobel E. Hemolytic transfusion reactions. Transfus Med Hemother. 2008;35:346\u201353.","journal-title":"Transfus Med Hemother"},{"issue":"1","key":"2378_CR13","first-page":"14","volume":"5","author":"DM Mosser","year":"2011","unstructured":"Mosser DM, Zhang X. Measuring opsonic phagocytosis via Fcgamma receptors and complement receptors on macrophages. Curr Protoc Immunol. 2011;5(1):14\u201327.","journal-title":"Curr Protoc Immunol"},{"key":"2378_CR14","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1182\/blood.V54.5.1131.1131","volume":"54","author":"RJ Kurlander","year":"1979","unstructured":"Kurlander RJ, Rosse WF. Monocyte-mediated destruction in the presence of serum of red cells coated with antibody. Blood. 1979;54:1131\u20139.","journal-title":"Blood"},{"key":"2378_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1172\/JCI109048","volume":"61","author":"RJ Kurlander","year":"1978","unstructured":"Kurlander RJ, Rosse WF, Logue GL. Quantitative influence of antibody and complement coating of red cells on monocyte-mediated cell lysis. J Clin Invest. 1978;61:1309\u201319.","journal-title":"J Clin Invest"},{"key":"2378_CR16","doi-asserted-by":"publisher","DOI":"10.3791\/55039","author":"TN Tong","year":"2017","unstructured":"Tong TN, Branch DR. Use of a monocyte monolayer assay to evaluate Fcgamma receptor-mediated phagocytosis. J Vis Exp. 2017. https:\/\/doi.org\/10.3791\/55039.","journal-title":"J Vis Exp"},{"key":"2378_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1182\/blood-2017-07-796151","volume":"131","author":"DR Branch","year":"2018","unstructured":"Branch DR, Hellberg A, Bruggeman CW, Storry JR, Sakac D, Blacquiere M, Tong TN, Burke-Murphy E, Binnington B, Parmar N, et al. ABO zygosity, but not secretor or Fc receptor status, is a significant risk factor for IVIG-associated hemolysis. Blood. 2018;131:830\u20135.","journal-title":"Blood"},{"key":"2378_CR18","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1182\/bloodadvances.2017008805","volume":"1","author":"P Pandey","year":"2017","unstructured":"Pandey P, Anani WQ, Gottschall JL, Denomme GA. Potential impact of complement regulator deficiencies on hemolytic reactions due to minor ABO-mismatched transfusions. Blood Adv. 2017;1:1977\u201382.","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2378_CR19","doi-asserted-by":"publisher","first-page":"114S","DOI":"10.1111\/trf.12045","volume":"53","author":"O Berseus","year":"2013","unstructured":"Berseus O, Boman K, Nessen SC, Westerberg LA. Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma. Transfusion. 2013;53(Suppl 1):114S\u201323S.","journal-title":"Transfusion"},{"key":"2378_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.transci.2009.10.013","volume":"42","author":"CD Josephson","year":"2010","unstructured":"Josephson CD, Castillejo MI, Grima K, Hillyer CD. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfus Apher Sci. 2010;42:83\u20138.","journal-title":"Transfus Apher Sci"},{"key":"2378_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1146\/annurev.immunol.17.1.593","volume":"17","author":"A Aderem","year":"1999","unstructured":"Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999;17:593\u2013623.","journal-title":"Annu Rev Immunol"},{"key":"2378_CR22","first-page":"491","volume":"66","author":"Z Rozsnyay","year":"1989","unstructured":"Rozsnyay Z, Sarmay G, Walker M, Maslanka K, Valasek Z, Jefferis R, Gergely J. Distinctive role of IgG1 and IgG3 isotypes in Fc gamma R-mediated functions. Immunology. 1989;66:491\u20138.","journal-title":"Immunology"},{"key":"2378_CR23","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.","journal-title":"Front Immunol"},{"key":"2378_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.bjhh.2015.05.001","volume":"37","author":"CS Landim","year":"2015","unstructured":"Landim CS, Gomes FC, Zeza BM, Mendrone-Junior A, Dinardo CL. Prophylactic strategies for acute hemolysis secondary to plasma-incompatible platelet transfusions: correlation between qualitative hemolysin test and isohemagglutinin titration. Rev Bras Hematol Hemoter. 2015;37:217\u201322.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"2378_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/eji.1830210103","volume":"21","author":"TE Michaelsen","year":"1991","unstructured":"Michaelsen TE, Garred P, Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol. 1991;21:11\u20136.","journal-title":"Eur J Immunol"},{"key":"2378_CR26","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/trf.15229","volume":"59","author":"GP Yung","year":"2019","unstructured":"Yung GP, Seebach JD, Baerenzung N, Pendergrast J, Cserti-Gazdewich C, Branch DR. Eluates from DAT-positive patients with or without hemolysis after high-dose IVIG yield predominantly IgG isoagglutinins of IgG2 subclass. Transfusion. 2019;59:1882\u20133.","journal-title":"Transfusion"},{"key":"2378_CR27","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1111\/trf.14996","volume":"58","author":"WA Flegel","year":"2018","unstructured":"Flegel WA, Henry SM. Can anti-A1 cause hemolysis? Transfusion. 2018;58:3036\u20137.","journal-title":"Transfusion"},{"key":"2378_CR28","volume-title":"Blood transfusion in clinical medicine","author":"PL Mollison","year":"1979","unstructured":"Mollison PL. Blood transfusion in clinical medicine. 6th ed. Oxford: Blackwell Scientific; 1979.","edition":"6"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02378-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-020-02378-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02378-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T20:36:20Z","timestamp":1622147780000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02378-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2378"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02378-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-17384\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The biospecimens used in this manuscript were provided with waiver of consent as approved by the Medical College of Wisconsin Institutional Review Board, project PRO00031384 and Versiti Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"There are no individual person identifiers in this manuscript. Consent for publication was not sought.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"216"}}